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ABSTRACT
Purpose: To assess the efficacy of monotherapy using tacrolimus eye drops ver-
sus sodium cromoglycate for the treatment of vernal keratoconjunctivitis (VKC).
Methods: Randomized double-masked controlled trial comparing the efficacy 
of tacrolimus 0.03% eye drops t.i.d. (Group 1) with sodium cromoglycate 4% eye 
drops t.i.d. (Group 2) for the symptomatic control of VKC at days 0, 15, 30, 45, and 
90 of follow-up. Visual acuity, intraocular pressure, and other complications were 
evaluated to assess safety and side effects.
Results: In total, 16 patients were included, with 8 enrolled in each group. Two 
patients from Group 2 were excluded from the analysis at days 45 and 90 because 
of corticosteroid use. Most patients were male (81.8%) and presented with limbal 
VKC (56.3%). There were statistically significant differences in favor of tacrolimus in 
the following severity scores: itching at day 90 (p=0.001); foreign body sensation 
at day 15 (p=0.042); photophobia at day 30 (p=0.041); keratitis at day 30 (p=0.048); 
and limbal activity at days 15 (p=0.011), 30 (p=0.007), and 45 (p=0.015). No relevant 
adverse effects were reported, except for a burning sensation with tacrolimus, 
though this did not compromise treatment compliance.
Conclusion: Treatment with tacrolimus was superior to sodium cromoglycate 
when comparing severity scores for symptoms of itching, foreign body sensation, 
and photophobia, as well as for signs of limbal inflammatory activity and keratitis.
Keywords: Conjunctivitis; Allergic; Anti-allergic agents; Tacrolimus; Ophthalmic 
solutions; Cromolyn sodium
RESUMO
Objetivo: Demonstrar a eficácia do colírio de tacrolimus 0,03% como único agente 
antialérgico versus o colírio de cromoglicato de sódio 4% no tratamento de cerato-
conjuntivite primaveril (CCP). 
Métodos: Ensaio clínico randomizado duplo-mascarado comparando a eficácia 
do colírio de tacrolimus 0,03% 3 vezes ao dia, versus o colírio de cromoglicato 4% 3 
vezes ao dia, no controle dos sintomas e sinais de pacientes com o diagnóstico de 
ceratoconjuntivite primaveril, durante o período de 3 meses, com avaliações nos dias 
0, 15, 30, 45 e 90. Acuidade visual, pressão intraocular e outras possíveis complicações 
foram avaliadas para determinar segurança e efeitos adversos.
Resultados: Dezesseis pacientes foram incluídos no estudo, sendo que oito fizeram uso 
de colírio de tacrolimus 0,03% (Grupo 1) e oito fizeram uso de colírio de cromoglicato 
de sódio 4% (Grupo 2). Dois pacientes do Grupo 2 foram excluídos da análise dos dias 
45 e 90, devido à necessidade de utilização de corticosteroide tópico. A maioria dos 
pacientes era do sexo masculino (81,8%) e 56,3% apresentavam a doença em sua 
forma limbar. Houve diferença estatisticamente significativa entre os Grupos 1 e 2 em 
relação à graduação de severidade para os sintomas de prurido no dia 90 (p=0,001), 
sensação de corpo estranho no dia 15 (p=0,042), fotofobia no dia 30 (p=0,041) e para 
os sinais de atividade inflamatória limbar nos dias 15 (p=0,011), 30 (p=0,007) e 45 
(p=0,015), e ceratite no dia 30 (p=0,048). Nenhum efeito adverso relevante foi notado, 
exceto queixa de queimação ocular quando da instilação de tacrolimus, o que não 
comprometeu à adesão ao tratamento. 
Conclusão: O colírio de tacrolimus 0,03% foi superior ao colírio de cromoglicato de 
sódio 4% comparando a graduação de severidade para os sintomas de prurido, sensação 
de corpo estranho e fotofobia, assim como para os sinais de atividade inflamatória 
limbar e ceratite, em determinados períodos de tempo durante o seguimento.
Descritores: Conjuntivite alérgica; Antialérgicos; Tacrolimo; Soluções oftálmicas; Cro-
molina sódica
INTRODUCTION
Ocular allergy is characterized by an inflammatory reaction of 
the ocular surface caused by hypersensitivity reactions type I or IV. 
Disease severity is related to the magnitude of the resulting inflam-
mation and is influenced by the patient’s age, as well as genetic and 
environmental factors. Types of ocular allergy include seasonal con-
junctivitis, perennial conjunctivitis, atopic keratoconjunctivitis, and 
vernal keratoconjunctivitis (VKC)(1).
VKC is a chronic, bilateral (though at times asymmetrical), seaso-
nally exacerbated, allergic inflammation of the tarsal conjunctiva, 
bulbar conjunctiva, or both. It is more common in children and 
young adults with known atopy, and typically presents with pruritus, 
hyperemia, photophobia, and watering(2). The conjunctival changes 
in VKC are the most pronounced of the subtypes of ocular allergy, 
being characterized by the formation of giant papillae in the upper 
tarsal conjunctiva and by swollen limbal lesions(3). The pathology also 
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differs from seasonal and perennial allergic conjunctivitis, because it 
is mediated by Th2 lymphocytes (type IV hypersensitivity reaction). 
However, the precise roles of mast cells, eosinophils, fibroblasts, and 
their cytokines in the inflammatory and remodeling processes of 
conjunctival tissue are yet to be established(3). Although conjunctival 
inflammation typically subsides and corneal lesions typically heal 
spontaneously beyond adolescence, individuals may be left with 
corneal scarring, opacities, and irregular astigmatism that can per-
manently reduce the quality of vision(3).
Broadly, the treatment of VKC is divided into preventive, clini-
cal, and surgical options. Preventive options involve eliminating or 
avoiding allergens like house dust mites and pollen, while surgical 
options involve scraping fibrin from non-healing shield ulcers or 
removing upper tarsal giant papillae; however, surgical options are 
reserved for severe cases(4). Regarding medical treatment, topical 
an tihistamines, mast cell stabilizers, and drugs with multiple actions 
(e.g., alcaftadine, olopatadine) are typical first-line options(4). Sodium 
cromoglycate is the most commonly used mast cell stabilizer, which 
acts by blocking the degranulation of inflammatory mediators, 
thereby inhibiting hypersensitivity reaction type I(5,6). The effects of 
mast cell stabilizers are noticeable 2 to 5 days after starting treat-
ment, but the maximum effect is only achieved by 15 days. Therefo-
re, sodium cromoglycate is best used to prevent recurrences of VKC 
after initial disease control. Topical corticosteroids are also useful 
when disease is severe. However, because steroids are associated 
with treatment-related adverse effects, such as cataract, glaucoma, 
and keratitis(7), they should be reserved for the management of 
acute allergic crises and for no more than 2 to 4 weeks(8,9).
Immunomodulators, such as tacrolimus and cyclosporine, have 
recently been used as treatment alternatives because of their potent 
anti-inflammatory effects and favorable side-effect profiles. Indeed, 
these agents have not only been used to replace corticosteroids for 
ocular allergic crises but also to replace other agents for the main-
tenance of controlled VKC. Tacrolimus is an immunosuppressant in 
the macrolide family, which includes cyclosporine. Its mechanism 
of action consists of decreasing the production of inflammatory 
mediators by T lymphocytes through the inhibition of calcineurin, an 
intracytoplasmic protein essential for interleukin (IL)-2 and IL-4 trans-
cription(10). It has been extensively studied because of its widespread 
use as an immunosuppressant to control rejection of solid organ 
trans plants(11) and because it is an effective agent in the treatment 
of autoimmune skin disorders like atopic dermatitis and vitiligo(12). 
Furthermore, it has been reported that tacrolimus inhibits histamine 
release from mast cells, impairs prostaglandin synthesis(13), and sup-
presses histamine release from basophils(14). These three actions may 
effectively reduce allergic symptoms in VKC.
An in vitro study has shown that the immunosuppressive effect of 
tacrolimus is 100-times higher than that of cyclosporine(15). Further-
more, it has been shown to be better tolerated(16). Numerous studies 
have also described the use of tacrolimus for the treatment of ocular 
disease, such as corneal graft rejection, Mooren’s ulcer, uveitis, and 
graft-versus-host disease(10,17). Tacrolimus may have similar efficacy to 
corticosteroids in both the control of allergic crises and in the mainte-
nance of stable disease, but may benefit from a lower incidence of 
adverse effects(18,19).
In routine practice, patients with ocular allergy often use a com-
bination of eye drops, which both increases the cost and compro-
mises treatment compliance. Given this and the putative benefits 
of tacrolimus, we wanted to evaluate the efficacy of topical mono-
therapy with tacrolimus compared with sodium cromoglycate for 
the treatment of VKC.
METHODS
Study deSign
This study was a prospective randomized double-masked clinical 
trial conducted at a single tertiary care center in São Paulo, Brazil. We 
compared the efficacy of topical tacrolimus 0.03% eye drops with 
sodium cromoglycate 4% eye drops for the treatment of VKC. The 
study was conducted in accordance with the Declaration of Helsinki 
and initiated after approval by the Research Ethics Committee of 
the São Paulo Hospital, Federal University of São Paulo under the 
CAAE number: 47393715.4.0000.5505.
Patient Selection
Patients were selected from the External Diseases and Cornea 
Outpatient Unit and from the Ophthalmic Emergency Care Unit. 
VKC was diagnosed based on chronic complaints of itching, foreign 
body sensation, photophobia, and tearing, together with typical 
findings of limbal inflammatory activity (i.e., limbal hyperemia and 
Horner-Trantas dots) and giant papillae on the upper tarsal conjunc-
tiva. We excluded patients who were younger than 7 years and older 
than 18 years, who had current ocular infections, who were using to-
pical tacrolimus, who had ever used a systemic immunosuppressant, 
or who had undergone supratarsal corticosteroid injection. Patients 
meeting the criteria for inclusion, together with their legal represen-
tatives, were asked to read and agree with informed consent forms.
trial Protocol
Individuals were allocated to two different groups in a 1:1 ratio 
based on previous block randomization (4 patients per block) with a 
random number table created using Stata 12® (StataCorp LP, TX, USA). 
Group 1 was to receive tacrolimus 0.03% eye drops every 8 h and 
Group 2 was to receive sodium cromoglycate 4% eye drops every 8 h 
(Both eye drops were obtained from Ophthalmos, São Paulo, Brazil). 
Patients, healthcare providers, and data collectors were masked to 
the treatment drug. For double-masking, the eye drop flasks were 
numbered and contained no identifying marks, and the contents of 
the flasks were only revealed at the end of the data collection period.
After the initial approach and group assignment, we applied a 
protocol for the objective assessment of signs and symptoms, adapted 
from clinical trials with similar methods and objectives(20-22). Symptoms 
of itching, foreign body sensation, photophobia, and tearing, in addi-
tion to signs of conjunctival hyperemia, upper tarsal pa pillae, limbal 
inflammatory activity, keratitis, and discharge, were assessed and 
graded by severity from 0 to 3, with higher scores indicating greater 
severity (Tables 1 and 2). Disease subtype was defined as follows: 
patients with grade 3 papillae and grade 0 or 1 limbi were classed as 
Table 1. Severity scores for symptoms of vernal keratoconjunctivitis
Symptom Severity score
Itching 0: absent, no desire to scratch
1+: intermittent desire to scratch
2+: frequent desire to scratch
3+: constant desire to scratch
Foreign body sensation 0: absent, no foreign body sensation
1+: discrete, similar to dust
2+: mild, similar to sand
3+: severe, constant, and similar to rock
Photophobia 0: absent, no photophobia
1+: mild, squints in bright light
2+: moderate, improves with use of sunglasses 
3+: severe, improves only with total eye occlusion
Tearing 0: absent
1+: humid, no epiphora
2+: intermittent epiphora
3+: constant epiphora
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having tarsal disease; patients with grade 0, 1, or 2 papillae and grade 
2 or 3 limbi were classed as having limbal disease; and all other pa-
tients were classed as having mixed tarsal-limbal disease. Symptoms 
and signs were assessed before and during therapy (i.e., at 0, 15, 30, 
45, and 90 days). Variables were analyzed individually, and because of 
the bilateral nature of VKC, evaluation was based on the examination 
of both eyes, but data was recorded for the worse eye.
No group was allowed concomitant treatment with any other 
anti-allergic eye drops or artificial tears. However, dexamethasone 
sodium phosphate 0.1% eye drops (Ophthalmos, São Paulo, Brazil) 
q.i.d. for 10 days were permitted if an allergic crisis developed. During 
follow-up, crises were defined as the presence of grade 2 or 3 limbal 
inflammatory activity, grade 1 or 2 keratitis, and symptoms compro-
mising daily life, or as the development of grade 3 keratitis (shield 
ulcer).
outcomeS
We assessed the change in severity scores for symptoms and 
signs during follow-up by comparison of scores between treatment 
groups at each follow-up point and by analyzing scores for each 
group separately over the study period. We also evaluated the safety 
and side effects of treatment by measuring visual acuity, intraocular 
pressures, and secondary infection and other complication rates.
StatiStical analySiS
Data were first analyzed descriptively, using absolute and relative 
frequencies for categorical variables and means and pattern-devia-
tion for numerical variables. Age comparison between treatment 
groups was performed using the Student’s t test for independent 
samples. Due to the small sample size, comparison of the distribu-
tion of VKC severity scores per treatment group were performed at 
each time point using Fisher’s exact test. To compare the evolution 
of severity scores separately in each treatment group during follow-up, 
we used Friedman’s non-parametric test. When differences were 
verified, comparison between follow-up periods was performed 
by Dunn-Bonferroni multiple comparisons to maintain the global 
significance level. For all statistical tests, a 5% significance level was 
adopted. Analyses were performed using IBM SPSS for Windows, 
Version 20.0 (IBM Corp., Armonk, NY, USA), and graphics elaboration 
was performed using Stata 12 (StataCorp LP, TX, USA).
RESULTS
ParticiPant characteriSticS
In total, 16 patients were included, with 8 per treatment group. 
All patients were analyzed from baseline until day 30 of follow-up, 
after which two patients in group 2 were excluded from further 
follow-up because they needed topical corticosteroids to manage 
allergic crises (Figure 1). There were no differences between the 
groups in the distribution by sex (p=0.200), age (p=0.154), or VKC 
subtype (p=0.151). Most patients were male (81.8%) and most pre-
sented with the limbal VKC subtype (56.3%) (Table 3).
differenceS in clinical SymPtomS between grouPS  
and time PointS
Regarding the severity scores in each group during follow-up, 
there were significant differences for itching (p<0.001), photophobia 
Table 2. Severity scores for signs of vernal keratoconjunctivitis
Sign Severity score
Conjunctival hyperemia 0: absent, calm conjunctiva
1+: mild, increase in vessel diameter, difficult to notice
2+: moderate, increase in diameter and number of 
vessels
3+: diffuse and intense hyperemia
Upper tarsal papillae 0: absent on the central tarsal conjunctiva
1+: present on the central tarsal conjunctiva
2+: some giant papillae
3+: giant papillae predominance
Limbus 0: no limbal inflammatory activity
1+: limbal hyperemia
2+: limbal hyperemia and papillae
3+: Horner-Trantas dots
Keratitis 0: absent, no epitheliopathy
1+: superficial punctate keratitis
2+: confluent punctate keratitis
3+: shield ulcer
Discharge 0: absent, no discharge
1+: little amount in the fornix
2+: moderate amount in the fornix
3+: great amount in the fornix, sticky eyes in the 
morning
Table 3. Homogeneity of the treatment groups
Drug 1 Drug 2 Total p
Sex 0.200a
Male 08 (100.0%) 5 (62.5%) 13 (81.3%)
Female 00 (000.0%) 3 (37.5%) 03 (18.8%)
VKC subtype 0.151a
Tarsal 04 (050.0%) 1 (12.5%) 05 (31.3%)
Limbal 04 (050.0%) 5 (62.5%) 09 (56.3%)
Mixed 00 (000.0%) 2 (25.0%) 02 (12.5%)
Age (years) 10.8 (2.4) 12.5 (2.3) 11.6 (2.4) 0.154a
The p-values are for Fisher’s exact test or Student’s t test (a). VKC = vernal keratoconjunctivitis
Figure 1. Study flowchart.
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(p=0.006), and tearing (p<0.001) in Group 1 when comparing days 
0-30-45-90. Differences were also significant for itching (p=0.020) 
when comparing days 0-30-45 and for foreign body sensation 
(p=0.047) when comparing days 0-45 in Group 2 (Figure 2, see letters 
a, b, and c). Differences in severity scores for itching, foreign body 
sensation, and photophobia were statistically significant between 
the treatment groups at days 90 (p=0.001), 15 (p=0.042), and 30 
(p=0.041), respectively, with group 2 experiencing more severe 
symptoms at each point (Figure 2, see asterisks).
differenceS in clinical SignS between grouPS and time PointS
In group 1, the decreases in severity scores were significant when 
comparing days 0-30-45-90 for conjunctival hyperemia (p<0.001) 
and days 0-30-45 for limbal inflammatory activity (p=0.006). In Group 
2, the decreases in severity scores were significant when comparing 
days 0-30-45 for conjunctival hyperemia (p=0.008) and when com-
paring days 0-45 for limbal inflammatory activity (p=0.007) (Figure 3, 
see letters a and b).
Differences in the severity scores for limbal inflammatory activity 
were statistically significant between the treatment groups at days 
15 (p=0.011), 30 (p=0.007), and 45 (p=0,015). They were also signifi-
cant for keratitis at day 30 (p=0.048). The decrease in severity scores 
for signs indicated greater improvement in Group 1 (Figure 3, see 
asterisks).
adverSe effectS
No relevant adverse effects were noted in either patient group, 
though patients complained of a burning sensation when tacrolimus 
was instilled. However, this did not affect compliance.
DISCUSSION
VKC and atopic keratoconjunctivitis are the most severe forms of 
ocular allergy, with visual loss a potential risk because of either the 
disease itself or indiscriminate corticosteroid use. In a retrospective 
study, Sacchetti et al.(23) observed that patients with worse VKC at 
presentation had more recurrences per year, more hospital visits, and 
worse final visual acuity. In another study, Bonini et al.(22) concluded 
that VKC generally has a good prognosis, with 52% of patients in their 
cohort showing persistent symptoms after a mean follow-up period 
of approximately 5 years; but, only 6% of their patients showed per-
manent reduction in visual acuity because of corneal damage.
In the present study, most patients in both groups had mild pre-
sentations. This may have been because they were seen in our tertiary 
care ophthalmic unit. Although we treat patients with more severe 
forms of ocular allergy, many were already being treated with tacro-
limus or had already undergone supratarsal corticosteroid injection. 
This also limited the number of patients with diagnosed VKC who met 
the inclusion criteria for our study.
Tacrolimus has been shown to be effective and safe for both the 
control of ocular allergic crises and for the maintenance of VKC(24-26). 
In a randomized clinical trial, Labcharoenwongs et al.(19) compared 
tacrolimus 0.1% with cyclosporine 2% and reported clinical improve-
ment in both groups, with no significant difference between the two 
drugs. However, Pucci et al.(27) performed a cross-over clinical trial 
comparing tacrolimus 0.1% and cyclosporine 1% for the treatment 
of severe VKC, and they demonstrated greater improvement in objec-
tive and subjective scores in eyes treated with tacrolimus. Recently, 
Müller et al.(21) compared tacrolimus alone versus tacrolimus plus 
olopatadine for the treatment of VKC. Although clinical improvement 
was reported in both groups, the difference was not statistically sig-
nificant, indicating the possibility of tacrolimus monotherapy for VKC. 
Our results support these findings, showing that tacrolimus was both 
effective and safe as monotherapy for VKC.
The increased numbers of CD4+ Th2 lymphocytes in the con-
junctiva, together with the increased expression of costimulatory 
molecules and cytokines, suggest that T cells play a crucial role in 
the development of VKC. In addition to typical Th2-derived cytoki-
nes, Th1-type cytokines, pro-inflammatory cytokines, and a variety 
of chemokines, growth factors, and enzymes are overly expressed in 
patients with VKC(28). Tacrolimus appears to control VKC by inhibiting 
T-cell activation via calcineurin inhibition, thereby reducing inflam-
matory cytokine production (i.e., IL-4 and IL-5) and the subsequent 
inflammatory reactions(26).
Among the reported adverse effects of topical tacrolimus are a 
local burning sensation and an itching sensation, both of which tend 
to improve with time. Moreover, adverse symptoms are usually tole-
rable, with only a few reports of patients needing to stop therapy(29). 
Only one case of herpes simplex recurrence has been reported(18). In 
our study, the only adverse effect was a burning sensation in the eye, 
and no patient presented with major adverse events or discontinued 
the drug. There are no literature reports of raised intraocular pressure 
with tacrolimus, so it is reasonable to assume that this drug is safe for 
patients with glaucoma, previous steroid-induced increased intraocu-
lar pressure, or those at risk of cataract formation.
Figure 2. Distribution of severity scores for vernal keratoconjunctivitis symptoms.
Figure 3. Distribution of severity scores for vernal keratoconjunctivitis signs.
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According to Attas-Fox et al.(24), blood levels of tacrolimus after 
topical use are clinically negligible. Ohashi et al.(18) compared different 
dosages of ophthalmic tacrolimus suspension (0.01%, 0.03%, and 
0.1%), and concluded that the 0.1% concentration was associated 
with the greatest symptom improvement with the same safety profile 
as the other preparations. Supporting this, Ebihara et al.(30) evaluated 
the blood levels of tacrolimus 0.1% ointment over 12 weeks, and they 
concluded that the maximum blood concentration remained below 
2 ng/mL, well below the level (10 ng/mL) at which the risk of systemic 
adverse drug reactions increases. In our experience, tacrolimus 0.03% 
eye drops produced good clinical outcomes, similar to the ointment 
formulation. Although both ointment and eye drops formulations of 
tacrolimus are available for ocular use in Brazil, this is only through 
compounding pharmacies, which limits their availability and com-
plicates rapid access.
We chose not to include any other topical medication to be gi-
ven during the follow-up period to avoid confounding factors and 
showed that tacrolimus could maintain all patients free from allergic 
crisis and improve symptoms and signs within 90 days. By contrast, 
two patients from group 2 were excluded from the statistical analysis 
after days 45 and 90 because of marked worsening of symptoms and 
signs that necessitated rescue therapy with topical corticosteroids. 
This difference in the incidence of allergic crisis was not statistically 
significant, and may be explained by either the small sample size, the 
possible differences in disease severity at baseline, or by the different 
efficacies of the drugs.
In the present study, strict monotherapy with either tacrolimus 
or sodium cromoglycate was compared. Our data indicate that ta-
crolimus 0.03% eye drops were superior to sodium cromoglycate 4% 
eye drops in alleviating the clinical symptoms (itching, foreign body 
sensation, and photophobia) and clinical signs (limbal inflammatory 
activity and keratitis) of patients with mild forms of VKC. Controlled 
studies with larger samples are needed to confirm our hypothesis 
that tacrolimus monotherapy is suitable for both acute crisis mana-
gement and maintenance in VKC.
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